Citations

Mayo Clinic

Showing 10 of 108523 citations.

Primary Care Occupational Therapy: Diagnoses, Outcomes, Reimbursement, and Team Satisfaction
Dahl-Popolizio, Sue, Sauber, Tina M., Ogaard, Mandi, Mookadam, Martina , Cambala, Shanthi V., Trembath, Felicia

The Open Journal of Occupational Therapy | July 16, 2024 | Volume: 12 | Issue: 3 | Pages: 1-13

10.15453/2168-6408.2266 Get It

Background: Literature supports including occupational therapists on primary care teams. Few occupational therapists practice in this setting. The health care community needs more information regarding the benefits of occupational therapists on the team. Method: We completed an 18-month pilot integrating an occupational therapist in a primary care team, tracking conditions treated by the occupational therapist, visit duration, reimbursement, and level of primary care providers’ (PCP) satisfaction. We then evaluated outcomes via a retrospective chart review. Results: Visits were brief, averaging 35 min. Longer visits did not improve outcomes. Occupational therapists were reimbursed by Medicare (47%), commercial (47%), both (6%). PCPs referred numerous conditions, and > 50% related to musculoskeletal pain. Most of the patients, 84%, reported partial (30%) or complete (54%) improvement; 60% required one-time treatment; and 40% were referred for further treatment on-site or outside the department for additional or specialty treatment. After the pilot, most of the PCPs felt an occupational therapist on the team was absolutely essential (n = 14; 61%), or very important (n = 7; 30%). Conclusion: Embedded occupational therapy treatment resulted in symptom improvement in 84% of patients across a variety of conditions, and brief visits were effective. Occupational therapist services were reimbursed across insurance plans. After working with an occupational therapist, 91% of the PCPs viewed the occupational therapist as a very important or essential team member.
Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer
Sabari, Joshua K. , Agrawal, Trishala, Zhou, Caicun , Girard, Nicolas , Mansfield, Aaron S. , Sanborn, Rachel E , Park, Keunchil

Future Oncology | July 16, 2024 | Volume: 20 | Issue: 32 | Pages: 2409-2421

10.1080/14796694.2024.2371698 | PMID 39012623 Get It

American Society of Transplant Surgeons Normothermic Regional Perfusion Standards: Abdominal
Croome, Kristopher P. , Bababekov, Yanik J. , Montenovo, Martin I. , Sellers, Marty T. , Foley, David P. , Abt, Peter, Mao, Shennen, Croome, Kris P , Brubaker, Aleah L. , Mao, Shennen A. , Pomfret, Elizabeth , Abt, Peter L.

Transplantation | July 16, 2024 | Volume: 108 | Issue: 8 | Pages: 1660-1668

10.1097/tp.0000000000005114 | PMID 39012956 Get It

Background. Normothermic regional perfusion (NRP) has emerged as a vital technique in organ procurement, particularly in donation after circulatory death (DCD) cases, offering the potential to optimize organ utilization and improve posttransplant outcomes. Recognizing its significance, the American Society of Transplant Surgeons (ASTS) convened a work group to develop standardized recommendations for abdominal NRP in the United States. Methods. The workgroup, comprising experts in NRP, DCD, and transplantation, formulated recommendations through a collaborative process involving revisions and approvals by relevant committees and the ASTS council. Four key areas were identified for standardization: Preprocedure communication, NRP procedure, Terminology and documentation, and Mentorship/credentialing. Results. The recommendations encompass a range of considerations, including preprocedure communication protocols to facilitate informed decision-making by transplant centers and organ procurement organizations, procedural guidelines for NRP teams, uniform terminology to clarify the NRP process, and standards for mentorship and credentialing of NRP practitioners. Specific recommendations address logistical concerns, procedural nuances, documentation requirements, and the importance of ongoing quality assurance. Conclusions. The standardized recommendations for abdominal NRP presented in this article aim to ensure consistency, safety, and efficacy in the organ procurement process. By establishing clear protocols and guidelines, the ASTS seeks to enhance organ utilization, honor donor wishes, and uphold public trust in the donation process. Implementation of these recommendations can contribute to the advancement of NRP practices and improve outcomes for transplant recipients.
What’s Important (Arts & Humanities): My Death Education
Noland, Shelley S.

Journal of Bone and Joint Surgery | July 16, 2024 | Volume: 106 | Issue: 21 | Pages: 2041

10.2106/jbjs.24.00315 | PMID 39012936 Get It

Update in the management of gastroenteropancreatic neuroendocrine tumors
Sedlack, Andrew J. H. , Naimian, Amirkia, Hallet, Julie , Halfdanarson, Thor, Capdevilla, Jaume, Rivero, Jaydira Del , Hallet, Julie , Del Rivero, Jaydira , Varghese, Diana Grace , Anari, Pouria Yazdian , Bodei, Lisa , Riechelmann, Rachel P.

Cancer | July 16, 2024 | Volume: 130 | Issue: 18 | Pages: 3090-3105

10.1002/cncr.35463 | PMID 39012928 Get It

Abstract Neuroendocrine neoplasms are a diverse group of neoplasms that can occur in various areas throughout the body. Well‐differentiated neuroendocrine tumors (NETs) most often arise in the gastrointestinal tract, termed gastroenteropancreatic neuroendocrine tumors (GEP‐NETs). Although GEP‐NETs are still uncommon, their incidence and prevalence have been steadily increasing over the past decades. The primary treatment for GEP‐NETs is surgery, which offers the best chance for a cure. However, because GEP‐NETs are often slow‐growing and do not cause symptoms until they have spread widely, curative surgery is not always an option. Significant advances have been made in systemic and locoregional treatment options in recent years, including peptide‐receptor radionuclide therapy with α and β emitters, somatostatin analogs, chemotherapy, and targeted molecular therapies.
Renovascular Disease and Mitochondrial Dysfunction in Human Mesenchymal Stem Cells
Eirin, Alfonso , Siddiqi, Sarosh , Hughes, A , Jiang, Yamei , Zhu, Xiang-Yang , Kazeminia, Sara , Lü, Bo , Li, Xing , Lu, Brandon , Xue, Ailing, Textor, Stephen C., Lerman, Lilach O. , Hughes, Autumn G , Xing, Li , Lerman, Amir , Lerman, Lilach O , Eirin, Alfonso , Kazeminia, Sara , Tang, Hui Jun , Lerman, Amir

Journal of the American Society of Nephrology | July 16, 2024 | Volume: 35 | Issue: 11 | Pages: 1507-1519

10.1681/asn.0000000000000440 | PMID 39012704 Get It

Key Points Renovascular disease impairs the capacity of human adipose tissue–derived mesenchymal stem/stromal cells to repair ischemic murine kidneys. miR-378h modulated the capacity of renovascular disease adipose tissue–derived mesenchymal stem/stromal cells to repair ischemic kidneys in vivo . Background Renovascular disease leads to renal ischemia, hypertension, and eventual kidney failure. Autologous transplantation of adipose tissue–derived mesenchymal stem/stromal cells (MSCs) improves perfusion and oxygenation in stenotic human kidneys, but associated atherosclerosis and hypertension might blunt their effectiveness. We hypothesized that renovascular disease alters the human MSC transcriptome and impairs their reparative potency. Methods MSCs were harvested from subcutaneous abdominal fat of patients with renovascular disease and healthy volunteers ( n =3 each), characterized and subsequently injected (5×10 5 /200 μ l) into mice 2 weeks after renal artery stenosis or sham surgery ( n =6/group). Two weeks later, mice underwent imaging and tissue studies. MSCs from healthy volunteers and in those with renovascular disease were also characterized by mRNA/microRNA (miRNA) sequencing. Based on these, MSC proliferation and mitochondrial damage were assessed in vitro before and after miRNA modulation and in vivo in additional renal artery stenosis mice administered with MSCs from renovascular disease pretreated with miR-378h mimic ( n =5) or inhibitor ( n =4). Results MSCs engrafted in stenotic mouse kidneys. Healthy volunteer MSCs (but not renovascular disease MSCs) decreased BP, improved serum creatinine levels and stenotic-kidney cortical perfusion and oxygenation, and attenuated peritubular capillary loss, tubular injury, and fibrosis. Genes upregulated in renovascular disease MSCs versus healthy volunteer MSCs were mostly implicated in transcription and cell proliferation, whereas those downregulated encoded mainly mitochondrial proteins. Upregulated miRNAs, including miR-378h, primarily target nuclear-encoded mitochondrial genes, whereas downregulated miRNAs mainly target genes implicated in transcription and cell proliferation. MSC proliferation was similar, but their mitochondrial structure and reparative function both in vivo and in vitro improved after miR-378h inhibition. Conclusions Renovascular disease impaired the reparative capacity of human MSCs, possibly by dysregulating miR-378h that targets mitochondrial genes. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_08_21_ASN0000000000000440.mp3
Targeting CEBPA to restore cellular identity and tissue homeostasis in pulmonary fibrosis
Tan, Qi , Wellmerling, Jack , Song, Shengren, Dresler, Sara R. , Meridew, Jeffrey A., Choi, Kyoung Moo , Li, Yong , Prakash, Y. S. , Tschumperlin, Daniel J. , Wellmerling, Jack H, Choi, Kyoung M, Prakash, Y S

JCI Insight | July 16, 2024 | Volume: 9 | Issue: 16 | Pages: No page available

10.1172/jci.insight.175290 | PMID 39012710 Get It

Fibrosis in the lung is thought to be driven by epithelial cell dysfunction and aberrant cell-cell interactions. Unveiling the molecular mechanisms of cellular plasticity and cell-cell interactions is imperative to elucidating lung regenerative capacity and aberrant repair in pulmonary fibrosis. By mining publicly available RNA-Seq data sets, we identified loss of CCAAT enhancer-binding protein alpha (CEBPA) as a candidate contributor to idiopathic pulmonary fibrosis (IPF). We used conditional KO mice, scRNA-Seq, lung organoids, small-molecule inhibition, and potentially novel gene manipulation methods to investigate the role of CEBPA in lung fibrosis and repair. Long-term (6 months or more) of Cebpa loss in AT2 cells caused spontaneous fibrosis and increased susceptibility to bleomycin-induced fibrosis. Cebpa knockout (KO) in these mice significantly decreased AT2 cell numbers in the lung and reduced expression of surfactant homeostasis genes, while increasing inflammatory cell recruitment as well as upregulating S100a8/a9 in AT2 cells. In vivo treatment with an S100A8/A9 inhibitor alleviated experimental lung fibrosis. Restoring CEBPA expression in lung organoids ex vivo and during experimental lung fibrosis in vivo rescued CEBPA deficiency–mediated phenotypes. Our study establishes a direct mechanistic link between CEBPA repression, impaired AT2 cell identity, disrupted tissue homeostasis, and lung fibrosis.
Patterns of brain volume and metabolism predict clinical features in the progressive supranuclear palsy spectrum
Ali, Farwa , Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Whitwell, Jennifer L. , Botha, Hugo , Clark, Heather, Jack, Clifford R , Josephs, Keith A , Whitwell, Jennifer , Botha, Hugo , Clark, Heather M. , Machulda, Mary M. , Senjem, Matthew L.

Brain Communications | July 16, 2024 | Volume: 6 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcae233 | PMID 39056025 Get It

Abstract Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy that presents with highly heterogenous clinical syndromes. We perform cross-sectional data-driven discovery of independent patterns of brain atrophy and hypometabolism across the entire PSP spectrum. We then use these patterns to predict specific clinical features and to assess their relationship to phenotypic heterogeneity. We included 111 patients with PSP (60 with Richardson syndrome and 51 with cortical and subcortical variant subtypes). Ninety-one were used as the training set and 20 as a test set. The presence and severity of granular clinical variables such as postural instability, parkinsonism, apraxia and supranuclear gaze palsy were noted. Domains of akinesia, ocular motor impairment, postural instability and cognitive dysfunction as defined by the Movement Disorders Society criteria for PSP were also recorded. Non-negative matrix factorization was used on cross-sectional MRI and fluorodeoxyglucose-positron emission tomography (FDG-PET) scans. Independent models for each as well as a combined model for MRI and FDG-PET were developed and used to predict the granular clinical variables. Both MRI and FDG-PET were better at predicting presence of a symptom than severity, suggesting identification of disease state may be more robust than disease stage. FDG-PET predicted predominantly cortical abnormalities better than MRI such as ideomotor apraxia, apraxia of speech and frontal dysexecutive syndrome. MRI demonstrated prediction of cortical and more so sub-cortical abnormalities, such as parkinsonism. Distinct neuroanatomical foci were predictive in MRI- and FDG-PET-based models. For example, vertical gaze palsy was predicted by midbrain atrophy on MRI, but frontal eye field hypometabolism on FDG-PET. Findings also differed by scale or instrument used. For example, prediction of ocular motor abnormalities using the PSP Saccadic Impairment Scale was stronger than with the Movement Disorders Society Diagnostic criteria for PSP oculomotor impairment designation. Combination of MRI and FDG-PET demonstrated enhanced detection of parkinsonism and frontal syndrome presence and apraxia, cognitive impairment and bradykinesia severity. Both MRI and FDG-PET patterns were able to predict some measures in the test set; however, prediction of global cognition measured by Montreal Cognitive Assessment was the strongest. MRI predictions generalized more robustly to the test set. PSP leads to neurodegeneration in motor, cognitive and ocular motor networks at cortical and subcortical foci, leading to diverse yet overlapping clinical syndromes. To advance understanding of phenotypic heterogeneity in PSP, it is essential to consider data-driven approaches to clinical neuroimaging analyses.
Transforming Healthcare: The AI Revolution in the Comprehensive Care of Hypertension
Alam, Sreyoshi F. , Alam, Sreyoshi Fatima , Suarez, Maria Lourdes Gonzalez

Clinics and Practice | July 16, 2024 | Volume: 14 | Issue: 4 | Pages: 1357-1374

10.3390/clinpract14040109 | PMID 39051303 Get It

This review explores the transformative role of artificial intelligence (AI) in hypertension care, summarizing and analyzing published works from the last three years in this field. Hypertension contributes to a significant healthcare burden both at an individual and global level. We focus on five key areas: risk prediction, diagnosis, education, monitoring, and management of hypertension, supplemented with a brief look into the works on hypertensive disease of pregnancy. For each area, we discuss the advantages and disadvantages of integrating AI. While AI, in its current rudimentary form, cannot replace sound clinical judgment, it can still enhance faster diagnosis, education, prevention, and management. The integration of AI in healthcare is poised to revolutionize hypertension care, although careful implementation and ongoing research are essential to mitigate risks.
Predictors of Shock‐Reduction Programming and Its Impact on Implantable Cardioverter‐Defibrillator Therapies and Mortality: The CERTITUDE Registry
Beyer, Sebastian E. , Harrell, Camden , Mullane, Steven , Kutyifa, Valentina , Madhavan, Malini , Piccini, Jonathan P. , Upadhyay, Gaurav A. , Ip, James E. , Thomas, George , Liu, Christopher F. , Markowitz, Steven M. , Hayes, David L. , Lerman, Bruce B. , Cheung, Jim W , Cheung, Jim W. , Ip, James E.

Journal of the American Heart Association | July 16, 2024 | Volume: 13 | Issue: 15 | Pages: No page available

10.1161/jaha.124.034500 | PMID 39011955 Get It

Background Shock‐reduction implantable cardioverter‐defibrillator programming (SRP) was associated with fewer therapies and improved survival in randomized controlled trials, but real‐world studies investigating SRP and associated outcomes are limited. Methods and Results The BIOTRONIK CERTITUDE registry was linked with the Medicare database. We included all patients with an implantable cardioverter‐defibrillator implanted between August 22, 2012 and September 30, 2021 in the United States. SRP was defined as programming to either a therapy rate cutoff ≥188 beats per minute or number of intervals to detection ≥30/40 for treatment. Among 6781 patients (mean 74±9 years; 27% women), 3393 (50%) had SRP. Older age, secondary prevention indication, and device implantation in the southern or western United States were associated with lower use of SRP. The cumulative incidence rate of implantable cardioverter‐defibrillator shocks was lower in the SRP group (5.1% shocks/patient year) compared with the non‐SRP group (7.2% shocks/patient year) (adjusted hazard ratio [HR], 0.83 [95% CI, 0.73–0.96]; P =0.005). Over a median follow‐up of 2.9 years, 739 deaths occurred in the SRP group and 822 deaths occurred in the non‐SRP group (adjusted HR, 0.97 [95% CI, 0.88–1.07]; P =0.569). SRP was associated with a lower all‐cause mortality among patients without ischemic heart disease compared with patients with ischemic heart disease (adjusted HR, 0.64 [95% CI, 0.48–0.87] versus adjusted HR, 1.02 [95% CI, 0.92–1.14]; P interaction =0.004). Conclusions Adoption of SRP is low in real‐world clinical practice. Age, clinical variables, and geographic factors are associated with use of SRP. In this study, SRP‐associated decrease in mortality was limited to patients without ischemic heart disease.